“…Intensive insulin therapy can be successful in Type 2 diabetic patients who fail to achieve good glycaemic control under conventional insulin therapy; however, reduction of blood glucose concentrations to near-normal levels often requires large doses of exogenous insulin, leading to increased plasma insulin levels and associated hyperinsulinaemia and weight gain. Several studies have demonstrated that treating Type 2 diabetic patients with exogenous insulin results in an average weight gain of 3-9% over pre-treatment weight [8][9][10]. In addition, intensive insulin therapy may influence other variables that are responsible for weight gain.…”
Section: Discussionmentioning
confidence: 99%
“…One approach to preventing weight gain is combination therapy, with oral hypoglycaemic agents during the day and long-acting insulin at night. This therapy has been shown to be as effective as MDI while associated with less weight gain [10]. Reduced weight gain despite effective blood glucose control may be attributable to elevated fasting blood glucose values, which contribute more to daytime hyperglycaemia than postprandial excursions [16].…”
Section: Discussionmentioning
confidence: 99%
“…To prevent weight gain secondary to insulin treatment, different forms of combination therapy have been investigated [8][9][10]. It has been shown that adding neutral protamine Hagedorn (NPH) insulin in the evening to therapy with oral hypoglycaemic agents improves glycaemic control in a similar manner to a twoinsulin injection regimen or a multiple-insulin injection regimen [10] and seems to induce less weight gain and hyperinsulinaemia. The most favourable outcome from combination therapy involved patients who still had some response to sulphonylureas or had evidence of relative endogenous secretion ability [8][9][10].…”
In the intent-to-treat analysis, CSII appeared to be superior to MDI in reducing HbA(1c) and glucose AUC values without significant change in weight or insulin dose in obese, uncontrolled, insulin-treated Type 2 diabetic subjects.
“…Intensive insulin therapy can be successful in Type 2 diabetic patients who fail to achieve good glycaemic control under conventional insulin therapy; however, reduction of blood glucose concentrations to near-normal levels often requires large doses of exogenous insulin, leading to increased plasma insulin levels and associated hyperinsulinaemia and weight gain. Several studies have demonstrated that treating Type 2 diabetic patients with exogenous insulin results in an average weight gain of 3-9% over pre-treatment weight [8][9][10]. In addition, intensive insulin therapy may influence other variables that are responsible for weight gain.…”
Section: Discussionmentioning
confidence: 99%
“…One approach to preventing weight gain is combination therapy, with oral hypoglycaemic agents during the day and long-acting insulin at night. This therapy has been shown to be as effective as MDI while associated with less weight gain [10]. Reduced weight gain despite effective blood glucose control may be attributable to elevated fasting blood glucose values, which contribute more to daytime hyperglycaemia than postprandial excursions [16].…”
Section: Discussionmentioning
confidence: 99%
“…To prevent weight gain secondary to insulin treatment, different forms of combination therapy have been investigated [8][9][10]. It has been shown that adding neutral protamine Hagedorn (NPH) insulin in the evening to therapy with oral hypoglycaemic agents improves glycaemic control in a similar manner to a twoinsulin injection regimen or a multiple-insulin injection regimen [10] and seems to induce less weight gain and hyperinsulinaemia. The most favourable outcome from combination therapy involved patients who still had some response to sulphonylureas or had evidence of relative endogenous secretion ability [8][9][10].…”
In the intent-to-treat analysis, CSII appeared to be superior to MDI in reducing HbA(1c) and glucose AUC values without significant change in weight or insulin dose in obese, uncontrolled, insulin-treated Type 2 diabetic subjects.
“…The use of premixed insulins is increasing world-wide. Under normal out-patient conditions, overall blood glucose control attained with twice-daily regimens may in some patients be as good as with multiple injection therapy [21][22][23].…”
Post-prandial glycaemic control was significantly improved, without increasing the risk of hypoglycaemia, and overall control was similar when people with Type 1 and Type 2 diabetes were treated on a twice-daily regimen with immediate premeal injections of BIAsp 30 compared with BHI 30.
“…Intensive insulin therapy is associated with weight gain which is generally an undesirable outcome [11,12]. In the UK Prospective Diabetes Study (UKPDS), intensive blood glucose control with insulin therapy was associated with a 6.5 kg weight gain [13].…”
HbA1C outcomes in the ambulatory care setting were generally not different between insulin classes. The likelihood of weight gain was less with insulin detemir than with insulin glargine. Thus, real-world weight outcomes for basal analog insulin may differ by specific product.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.